ATE245444T1 - Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen - Google Patents

Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen

Info

Publication number
ATE245444T1
ATE245444T1 AT99906749T AT99906749T ATE245444T1 AT E245444 T1 ATE245444 T1 AT E245444T1 AT 99906749 T AT99906749 T AT 99906749T AT 99906749 T AT99906749 T AT 99906749T AT E245444 T1 ATE245444 T1 AT E245444T1
Authority
AT
Austria
Prior art keywords
asparaginase
treatment
pharmaceutical composition
composition containing
hiv infections
Prior art date
Application number
AT99906749T
Other languages
English (en)
Inventor
Vassilios I Avramis
Lewis Cohen
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE245444T1 publication Critical patent/ATE245444T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
AT99906749T 1998-02-09 1999-02-09 Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen ATE245444T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7406698P 1998-02-09 1998-02-09
PCT/US1999/002480 WO1999039732A1 (en) 1998-02-09 1999-02-09 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Publications (1)

Publication Number Publication Date
ATE245444T1 true ATE245444T1 (de) 2003-08-15

Family

ID=22117505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906749T ATE245444T1 (de) 1998-02-09 1999-02-09 Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen

Country Status (10)

Country Link
EP (1) EP1053012B1 (de)
JP (1) JP2002502826A (de)
AT (1) ATE245444T1 (de)
AU (1) AU752434B2 (de)
CA (1) CA2319356A1 (de)
DE (1) DE69909747T2 (de)
DK (1) DK1053012T3 (de)
ES (1) ES2203072T3 (de)
WO (1) WO1999039732A1 (de)
ZA (1) ZA991029B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181045A4 (de) * 1999-04-02 2003-04-23 Los Angeles Childrens Hospital Verwendung von asparaginase und glutaminase zur behandlung von autoimmunerkrankungen sowie erkrankungen der abstossung von knochenmark und empfänger
AU6894400A (en) * 1999-08-06 2001-03-05 Enzon Pharmaceuticals Inc. Composition and methods for treatment of HIV infection
KR100777195B1 (ko) 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 송달성 물질 및 이를 이용한 약물 송달 시스템
WO2002085358A2 (en) * 2001-04-20 2002-10-31 Vion Pharmaceuticals, Inc. Antiviral agents and methods of treating viral infections
JP5271475B2 (ja) 2002-11-26 2013-08-21 ザ ユニヴァーシティー オヴ シカゴ 微生物媒介上皮疾患の予防及び治療のための材料並びに方法
WO2006029507A1 (en) * 2004-09-13 2006-03-23 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of feline calicivirus replication by asparaginase
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2015033344A1 (en) * 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
TWI762743B (zh) * 2017-11-29 2022-05-01 日商大鵬藥品工業股份有限公司 磺醯胺化合物及其用途
CN115671102A (zh) * 2022-11-17 2023-02-03 中国科学院大学 3-ap在制备抑制痘病毒的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2600256B1 (fr) * 1986-06-19 1988-09-16 Inst Nat Sante Rech Med Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
ES2217566T3 (es) * 1997-06-09 2004-11-01 Childrens Hospital Of Los Angeles Uso de asparaginasa de wolinella succionogenes para tratar enfermedades asociadas con la dependencia de asparagina.

Also Published As

Publication number Publication date
AU752434B2 (en) 2002-09-19
EP1053012B1 (de) 2003-07-23
DE69909747D1 (de) 2003-08-28
ES2203072T3 (es) 2004-04-01
CA2319356A1 (en) 1999-08-12
EP1053012A1 (de) 2000-11-22
WO1999039732A1 (en) 1999-08-12
ZA991029B (en) 1999-09-30
JP2002502826A (ja) 2002-01-29
AU2658499A (en) 1999-08-23
DE69909747T2 (de) 2004-04-15
DK1053012T3 (da) 2003-11-17

Similar Documents

Publication Publication Date Title
MY138860A (en) Hiv protease inhibitors.
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
DE69531944D1 (de) Neue hiv-protease-inhibitoren
ME00181B (me) Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
ATE238998T1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69430385D1 (de) Hiv-proteaseinhibitoren
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ES2132383T3 (es) Inhibidores de proteasa hiv.
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
ATE383161T1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
EE9700165A (et) Ühendite kombinatsioon, meetod ja farmatseutiline kompositsioon HIV proteaasi ja HIV pöördtranskriptaasi inhibeerimiseks ning HIV infektsiooni vältimiseks või raviks, või AIDS-i või ARC raviks
GB9930768D0 (en) Composition
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
IT1318424B1 (it) Composti con attivita' anti-hiv.
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
TR199902508T2 (xx) HIV proteaz inhibit�rleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053012

Country of ref document: EP

REN Ceased due to non-payment of the annual fee